Try our Advanced Search for more refined results

MANSON v. SCHERING-PLOUGH CORPORATION et al

  1. August 29, 2013

    Special Masters Back Atty Fee Bid In $688M Vytorin Deal

    Two special masters recommended Wednesday that a New Jersey federal court approve $140 million in attorneys' fees sought by class counsel who settled for $688 million two securities class actions alleging Merck & Co. and its Schering-Plough subsidiary hid test results on the efficacy of their anti-cholesterol drug Vytorin.

  2. August 06, 2013

    Merck Investors Rip Fee Requests In $688M Vytorin Deal

    Investors in two class actions alleging Merck & Co. and its Schering-Plough subsidiary hid test results for their anti-cholesterol drug Vytorin challenged a proposed $688 million settlement of the cases on Monday, saying attorneys' fee requests in the actions were too high.

  3. February 14, 2013

    Record $688M Merck Settlement May Not Be Contagious

    Despite the eye-popping size of Merck & Co.'s record $688 million stock-drop settlement Thursday, experts say the deal might not prove to be a tipping point in securities fraud cases that target deep-pocketed pharmaceutical firms.

  4. February 14, 2013

    Merck To Pay $688M To Settle Investor Suits Over Vytorin

    Merck & Co. said Thursday it will pay $688 million to settle two class actions alleging the drugmaker and subsidiary Schering-Plough hid test results for their anti-cholesterol drug Vytorin from investors, inking what plaintiffs' attorneys called one of the top 25 securities class action settlements ever.

  5. September 26, 2012

    Merck Investors Win Class Cert. In 2 Suits Over Vytorin

    A New Jersey federal judge on Tuesday granted class certification in a pair of related suits brought by investors claiming drugmaker Merck & Co. and subsidiary Schering-Plough hid test results that showed their anti-cholesterol drug Vytorin did not work.